Richard Pestell, MD
Dr. Richard Pestell is a clinician scientist who was appointed an Officer of the Order of Australia in the 2019 Queen's Birthday Honors for distinguished service to medicine, and to medical education, as a researcher and physician in the fields of endocrinology and oncology.
EcoGenome is a life science company dedicated to the development of prognostic and predictive tests that will enhance personalized treatment strategies for cancer patients, to improve outcomes, and reduce costs. We work on developing tests to inform the use of cancer therapies by identifying genetic vulnerabilities within the patient’s tumor.
Mid Atlantic Bio:
David Horn, MD
Dr. Horn brings over 30 years of research expertise in infectious diseases and is board-certified in internal medicine and infectious diseases. Prior to founding Mid-Atlantic Biotherapeutics, Dr. Horn held senior positions in Medical Services and Clinical Development at Merck & Co., Inc., and Professional Services and Medical Affairs at Bristol-Myers Squibb.
MABT’s mission is to bring novel immunotherapies to market, targeting multiple infectious disease indications with high unmet medical need, like rabies and coronaviruses. We employ a proprietary immunotherapy platform called IMT504.
View website here.
Gene Lancet Bio:
Minghong Zhong, PhD
Dr. Zhong, CSO and President, is an accomplished scientist with strong expertise in nucleic acid chemistry, medicinal chemistry and biochemistry. He has authored and co-authored more than 20 peer-reviewed research publications in these areas, and is the inventor or co-inventor of 4 granted U.S. patents and more than 8 patent applications that are currently under examination. He received his PhD in Chemistry from Brigham Young University and completed his postdoctoral training in molecular biophysics and biochemistry at Yale University, where he worked on ribosomes (an RNP complex) in Strobel lab in collaboration with Nobel Prize laureate Dr. Thomas Steitz. Afterwards, he completed a research fellowship in medicinal chemistry at the National Cancer Institute, NIH.
Gene Lancet Biosciences, a gene-editing company, owns a novel guide RNA (lgRNA) of distinct intellectual property designed for use in RNA-guided endonucleases as gene editing tools and human therapeutics. GeneLancet also develops non-immunogenic scarless STAR Editor, a novel CRISPR-Cas9/lgRNA complex, for curing chronic HBV, HIV, Alzheimer’s and other diseases of unmet needs.
View website here.